Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports

被引：4

作者：

Zanetta, Chiara ^{[1
]}

Filippi, Massimo ^{[1
,2
,3
,4
,5
]}

Moiola, Lucia ^{[1
]}

机构：

[1] IRCCS, San Raffaele Sci Inst, Neurol Unit, Via Olgettina 60, I-20132 Milan, Italy

[2] IRCCS, San Raffaele Sci Inst, Neurorehabilitat Unit, Milan, Italy

[3] IRCCS, San Raffaele Sci Inst, Div Neurosci, Neuroimaging Res Unit, Via Olgettina 60, I-20132 Milan, Italy

[4] IRCCS, San Raffaele Sci Inst, Neurophysiol Serv, Via Olgettina 60, I-20132 Milan, Italy

[5] Univ Vita Salute San Raffaele, Milan, Italy

来源：

NEUROLOGICAL SCIENCES | 2021年 / 42卷 / SUPPL 1期

关键词：

Case report; Fingolimod; Multiple sclerosis; Pediatric;

D O I：

10.1007/s10072-021-05270-7

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Approximately 3-10% of patients with multiple sclerosis (MS) have onset during childhood. Pediatric MS is characterized by a relapsing-remitting course and a high relapse rate. In 2010, fingolimod (Gilenya (R)) was approved in the USA for the treatment of relapsing-remitting MS in adults. In 2018, both the United States Food and Drug Administration and the European Medicines Agency expanded the approved indications of fingolimod to include its use in children with relapsing MS, and the drug was approved in Italy for this indication in September 2020. We describe two cases of children with relapsing-remitting MS who were treated with fingolimod at IRCCS Ospedale San Raffaele Multiple Sclerosis Center (Milan, Italy) for more than 2 years. Our real-world data confirm that fingolimod is an effective therapeutic strategy for children with relapsing MS, and its use could be considered in pediatric patients with active disease.

引用

页码：9 / 13

页数：5

共 50 条

[31] Adherence to therapeutic recommendation in relapsing-remitting multiple sclerosis patients [J].

Chojdak-Lukasiewicz, Justyna ;

Koltuniuk, Aleksandra ;

Sawicka, Ewa ;

Pokryszko-Dragan, Anna .

FRONTIERS IN IMMUNOLOGY, 2025, 16

[32] Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis [J].

Landi, D. ;

Vollaro, S. ;

Pellegrino, G. ;

Mulas, D. ;

Ghazaryan, A. ;

Falato, E. ;

Pasqualetti, P. ;

Rossini, P. M. ;

Filippi, M. M. .

CLINICAL NEUROPHYSIOLOGY, 2015, 126 (01) :165-169

[33] Emerging Therapies in Relapsing-Remitting Multiple Sclerosis [J].

Marriott, James J. ;

O'Connor, Paul W. .

REVIEWS ON RECENT CLINICAL TRIALS, 2010, 5 (03) :179-188

[34] Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation [J].

Berger, Benjamin ;

Baumgartner, Annette ;

Rauer, Sebastian ;

Mader, Irina ;

Luetzen, Niklas ;

Farenkopf, Ulrich ;

Stich, Oliver .

JOURNAL OF NEUROIMMUNOLOGY, 2015, 282 :118-122

[35] Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study [J].

Filippi, Massimo ;

Pagani, Elisabetta ;

Turrini, Renato ;

Bartezaghi, Marta ;

Morra, Vincenzo Brescia ;

Borriello, Giovanna ;

Clerici, Valentina Torri ;

Mirabella, Massimiliano ;

Pasquali, Livia ;

Patti, Francesco ;

Totaro, Rocco ;

Gallo, Paolo ;

Rocca, Maria A. .

JOURNAL OF NEUROLOGY, 2024, :6181-6196

[36] Real-world effectiveness of fingolimod in Polish group of patients with relapsing-remitting multiple sclerosis [J].

Walczak, Agata ;

Kurkowska-Jastrzebska, Iwona ;

Zakrzewska-Pniewska, Beata ;

Dorobek, Malgorzata ;

Brola, Waldemar ;

Zajdel, Radoslaw ;

Bartosik-Psujek, Halina ;

Stasiolek, Mariusz ;

Kulakowska, Alma ;

Rusek, Stanislaw ;

Tutaj, Andrzej ;

Glabinski, Andrzej ;

Wlodek, Agata ;

Kochanowski, Jan ;

Ciach, Agnieszka ;

Siger, Malgorzata ;

Kurowska, Katarzyna ;

Wicha, Wojciech ;

Nojszewska, Monika ;

Podlecka-Pietowska, Aleksandra ;

Czajka, Anna ;

Kapica-Topczewska, Katarzyna ;

Bielecki, Bartosz ;

Maciagowska-Terela, Marzena ;

Stepien, Adam .

CLINICAL NEUROLOGY AND NEUROSURGERY, 2019, 184

[37] Index of cardiac-electrophysiological balance in relapsing-remitting multiple sclerosis patients treated with fingolimod [J].

Gunay-Polatkan, S. ;

Gullu, G. ;

Sigirli, D. ;

Koc, E. R. ;

Aydinlar, A. ;

Turan, O. F. .

MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 76

[38] Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients [J].

Cannizzaro, Miryam ;

Ferre, Laura ;

Clarelli, Ferdinando ;

Giordano, Antonino ;

Sangalli, Francesca ;

Colombo, Bruno ;

Comi, Giancarlo ;

Moiola, Lucia ;

Martinelli, Vittorio ;

Filippi, Massimo ;

Esposito, Federica .

JOURNAL OF NEUROLOGY, 2022, 269 (10) :5596-5605

[39] Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia [J].

Lasalvia, Pieralessandro ;

Hernandez, Fabian ;

Castaneda-Cardona, Camilo ;

Andres Cuestas, J. ;

Rosselli, Diego .

VALUE IN HEALTH REGIONAL ISSUES, 2020, 23 :13-18

[40] Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis [J].

Grahl, S. ;

Bussas, M. ;

Wiestler, B. ;

Eichinger, P. ;

Gaser, C. ;

Kirschke, J. ;

Zimmer, C. ;

Berthele, A. ;

Hemmer, B. ;

Muehlau, M. .

NEUROTHERAPEUTICS, 2021, 18 (04) :2589-2597

← 1 2 3 4 5 →